Alongside cholinesterase inhibitors, the primary glutamatergic approach for AD is the non-competitive NMDA antagonist memantine, which exhibits a modest affinity for the NMDA receptor and is characterized by a quick onset and offset of activity, which is often associated with moderate to severe AD [107]. Here, BCHE is linked to Alzheimer disease.